Genomma Lab Internacional, S.A.B. de C.V.
GNMLF
$1.43
$0.169913.48%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 269.97M | 247.31M | 201.13M | 257.63M | 247.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 269.97M | 247.31M | 201.13M | 257.63M | 247.10M |
| Cost of Revenue | 97.15M | 85.88M | 80.59M | 96.84M | 96.44M |
| Gross Profit | 172.82M | 161.42M | 120.54M | 160.80M | 150.66M |
| SG&A Expenses | 116.13M | 111.02M | 76.26M | 108.40M | 104.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -371.90K | -105.90K | 4.51M | 453.00K | -2.88M |
| Total Operating Expenses | 212.90M | 196.80M | 161.36M | 205.69M | 197.85M |
| Operating Income | 57.07M | 50.51M | 39.77M | 51.94M | 49.25M |
| Income Before Tax | 48.91M | 30.46M | 6.06M | 32.16M | 32.50M |
| Income Tax Expenses | 12.25M | 8.54M | 9.55M | 10.42M | 8.90M |
| Earnings from Continuing Operations | 36.66M | 21.92M | -3.49M | 21.74M | 23.60M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.66M | 21.92M | -3.49M | 21.74M | 23.60M |
| EBIT | 57.07M | 50.51M | 39.77M | 51.94M | 49.25M |
| EBITDA | 60.54M | 55.81M | 41.89M | 55.48M | 52.71M |
| EPS Basic | 0.04 | 0.02 | 0.00 | 0.02 | 0.02 |
| Normalized Basic EPS | 0.03 | 0.02 | 0.00 | 0.02 | 0.02 |
| EPS Diluted | 0.04 | 0.02 | 0.00 | 0.02 | 0.02 |
| Normalized Diluted EPS | 0.03 | 0.02 | 0.00 | 0.02 | 0.02 |
| Average Basic Shares Outstanding | 942.75M | 954.12M | 940.11M | 950.44M | 970.69M |
| Average Diluted Shares Outstanding | 942.75M | 954.12M | 940.11M | 950.44M | 970.69M |
| Dividend Per Share | -- | 0.01 | 0.01 | 0.01 | 0.01 |
| Payout Ratio | 32.96% | 51.55% | -314.84% | 52.25% | 46.59% |
